Download
s00277-020-04325-7.pdf 736,19KB
WeightNameValue
1000 Titel
  • Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes
1000 Autor/in
  1. Kasprzak, Annika |
  2. Nachtkamp, K. |
  3. Kondakci, M. |
  4. Schroeder, T. |
  5. Kobbe, G. |
  6. Kündgen, A. |
  7. Kaivers, J. |
  8. Rautenberg, C. |
  9. Haas, R. |
  10. Gattermann, N. |
  11. Bonadies, N. |
  12. Germing, U. |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-11-07
1000 Erschienen in
1000 Quellenangabe
  • 100(2):455-463
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00277-020-04325-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817552/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • The European Leukemia Net (ELN) guidelines for treatment of myelodysplastic syndromes (MDS) connect heterogeneous MDS subgroups with a number of therapeutic options ranging from best supportive care to allogeneic stem cell transplantation (alloSCT). However, it is currently unknown whether adherence to guideline recommendations translates into improved survival. The sizeable database of the Duesseldorf MDS Registry allowed us to address this question. We first performed a retrospective analysis including 1698 patients (cohort 1) to whom we retrospectively applied the ELN guidelines. We compared patients treated according to the guidelines with patients who deviated from it, either because they received a certain treatment though it was not recommended or because they did not receive that treatment despite being eligible. We also performed a prospective study with 381 patients (cohort 2) who were seen in our department and received guideline-based expert advice. Again, we compared the impact of subsequent guideline-adherent versus non-adherent treatment. For the majority of treatment options (best supportive care, lenalidomide, hypomethylating agents, low-dose chemotherapy, and intensive chemotherapy), we found that adherence to the ELN guidelines did not improve survival in cohort 1. The same was true when patient management was prospectively enhanced through guideline-based treatment advice given by MDS experts (cohort 2). The only exceptions were alloSCT and iron chelation (ICT). Patients receiving ICT and alloSCT as recommended fared significantly better than those who were eligible but received other treatment. Our analysis underscores the limited survival impact of most MDS therapies and suggests to pursue alloSCT in all suitable candidates. Graphical abstract.
1000 Sacherschließung
lokal Female [MeSH]
lokal Myelodysplastic syndrome
lokal Hypomethylating agents
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Lenalidomide
lokal Myelodysplastic Syndromes/therapy [MeSH]
lokal Hematopoietic Stem Cell Transplantation [MeSH]
lokal Retrospective Studies [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/administration
lokal Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH]
lokal Original Article
lokal Survival Rate [MeSH]
lokal Databases, Factual [MeSH]
lokal Male [MeSH]
lokal Disease-Free Survival [MeSH]
lokal Guideline Adherence [MeSH]
lokal Iron chelation therapy
lokal Hematopoietic stem cell transplantation
lokal Guideline adherence
lokal Myelodysplastic Syndromes/mortality [MeSH]
lokal Transplantation, Homologous [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-7642-6751|https://frl.publisso.de/adhoc/uri/TmFjaHRrYW1wLCBLLg==|https://frl.publisso.de/adhoc/uri/S29uZGFrY2ksIE0u|https://frl.publisso.de/adhoc/uri/U2Nocm9lZGVyLCBULg==|https://frl.publisso.de/adhoc/uri/S29iYmUsIEcu|https://frl.publisso.de/adhoc/uri/S8O8bmRnZW4sIEEu|https://frl.publisso.de/adhoc/uri/S2FpdmVycywgSi4=|https://frl.publisso.de/adhoc/uri/UmF1dGVuYmVyZywgQy4=|https://frl.publisso.de/adhoc/uri/SGFhcywgUi4=|https://frl.publisso.de/adhoc/uri/R2F0dGVybWFubiwgTi4=|https://frl.publisso.de/adhoc/uri/Qm9uYWRpZXMsIE4u|https://frl.publisso.de/adhoc/uri/R2VybWluZywgVS4=
1000 Hinweis
  • DeepGreen-ID: 551480d1018a4ffcbf1398627b4650ad ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6467034.rdf
1000 Erstellt am 2023-11-17T05:51:31.958+0100
1000 Erstellt von 322
1000 beschreibt frl:6467034
1000 Zuletzt bearbeitet 2023-12-01T05:21:43.547+0100
1000 Objekt bearb. Fri Dec 01 05:21:43 CET 2023
1000 Vgl. frl:6467034
1000 Oai Id
  1. oai:frl.publisso.de:frl:6467034 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source